Videos

Ann Childress, MD, the current president of APSARD, invites you to attend this year's conference!

Love over hate is crucial, now more than ever.

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.

"Things fall apart; the centre cannot hold; Mere anarchy is loosed upon the world..."

Many social psychiatric challenges are worse, a year later...

"Spray the perfume of your smiles on the incision. Inject the song of life into my veins to wake me up. Gently beat the drum so my mind may dance with yours, my doctor, day and night."

"...my eyes searching for the one skater in every crowd who glides graceful as a god, like my father years ago in his black leather racing skates..."

You've heard of social capital and financial capital... but what about psychiatric capital?

Is finding meaning conducive to healing?

"My black cat sprints through the kitchen door, a glassy-eyed cottontail hanging limp from his jaws."

"Walk through the garden's dormant splendor. Say only, thank you."

Dr Moffic thanks those who fostered his faith.

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.

Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.

Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.

Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.

Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.

Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.

Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.

Don't miss this ACNP 2023 Annual Meeting session!

Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).

"You will love again the stranger who was your self."

Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.

Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.

Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.

Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.

Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.